ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,612.33
      1.25%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Kazia Therapeutics Ltd (KZIA)

      7. Kazia Therapeutics Ltd (KZIA) News

      KZIA

      Kazia Therapeutics (KZIA)

      Kazia Therapeutics Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KZIA
      DateTimeSourceHeadlineSymbolCompany
      12/15/20234:49PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
      12/06/20238:31AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      12/05/20236:02PMPR Newswire (US)Kazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
      12/04/20234:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
      12/01/20238:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      12/01/20238:00AMPR Newswire (US)Kazia Therapeutics Announces $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
      11/29/20234:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      11/29/20234:02PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      11/29/20237:01AMPR Newswire (US)KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNASDAQ:KZIAKazia Therapeutics Ltd
      11/21/20237:30AMPR Newswire (US)KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
      11/20/20234:39PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      11/20/20234:30PMPR Newswire (US)KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATIONNASDAQ:KZIAKazia Therapeutics Ltd
      11/15/20239:13AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      11/15/20238:30AMPR Newswire (US)KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
      11/10/20237:01AMPR Newswire (US)KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMANASDAQ:KZIAKazia Therapeutics Ltd
      11/01/20234:17PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      11/01/20237:01AMPR Newswire (US)KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMANASDAQ:KZIAKazia Therapeutics Ltd
      10/26/20237:56AMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:KZIAKazia Therapeutics Ltd
      10/23/20238:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      10/23/20237:01AMPR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDYNASDAQ:KZIAKazia Therapeutics Ltd
      10/13/20234:08PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      10/11/20237:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      10/11/20237:01AMPR Newswire (US)Kazia announces voluntary delisting from ASXNASDAQ:KZIAKazia Therapeutics Ltd
      10/10/20233:04PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      10/06/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      10/05/20237:01AMPR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGSNASDAQ:KZIAKazia Therapeutics Ltd
      09/29/20237:01AMPR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
      09/29/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      09/05/20237:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
      08/11/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
       Showing the most relevant articles for your search:NASDAQ:KZIA